Direct pharmacological activation of AMPK with the compound 991 extended lifespan in fission yeast, nematodes and fruit flies, and produced a proteomic signature associated with longevity in mice. Because 991 binds AMPK directly, the result isolates the kinase itself as the mediator of lifespan extension, unlike indirect activators such as metformin whose multiple mechanisms confound interpretation. It establishes AMPK as a pharmacologically tractable target rather than a downstream correlate of caloric restriction.
Key Points
- Compound 991 extended lifespan in yeast, worms and flies.
- Direct AMPK binding isolates the kinase from metformin's confounded mechanisms.
- Mice showed a pro-longevity proteomic profile after 991 treatment.
Longevity Analysis
AMPK sits at the junction where cellular energy status is read and translated into decisions about whether to build or to recycle — the same node engaged by fasting, caloric restriction and sustained aerobic work. Isolating its activation pharmacologically clarifies which part of the metformin literature is actually attributable to energy sensing, and which is not. Whether a direct activator can replicate what conserved behavioural inputs already achieve in mammals remains the open question, and nothing here displaces the metabolic conditions that keep the sensor responsive in the first place.
Original published by Wiley Aging Cell, by Eliano dos Santos, Marie Blickling, Fiona C. Leiper, John‐Patrick Alao, Claudia Lennicke, Andrea Foley, Jon R. Wilson, Steven J. Gamblin, Bénédicte Chazaud, Giovanna Lollo, Rémi Mounier, Gaëtan Juban, Charalampos Rallis, David Carling, Filipe Cabreiro, Helena M. Cochemé .